Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Public ClinicalTrials.gov record NCT04956640. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Study identification
- NCT ID
- NCT04956640
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 540 participants
Conditions and interventions
Conditions
Interventions
- LY3537982 Drug
- Pembrolizumab Drug
- Cetuximab Drug
- Pemetrexed Drug
- Cisplatin Drug
- Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 19, 2021 (Actual)
- Primary completion
- Apr 2027 (Estimated)
- Completion
- Apr 2027 (Estimated)
- Last update posted
- May 29, 2026
2021 – 2027
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| USC Norris Cancer Hospital | Los Angeles | California | 90033 | — |
| Chao Family Comprehensive Cancer Ctr. | Orange | California | 92868 | — |
| Yale-New Haven Hospital | New Haven | Connecticut | 06510 | — |
| AdventHealth Orlando | Orlando | Florida | 32803 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34236 | — |
| Indiana Univ Melvin & Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Community Health Network | Indianapolis | Indiana | 46250 | — |
| Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana | 70809 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| NYU Langone Health- Long Island | Mineola | New York | 11501 | — |
| NYU Langone | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Novant Health Cancer Institute - Elizabeth | Charlotte | North Carolina | 28204 | — |
| Novant Health Cancer Institute - Forsyth | Winston-Salem | North Carolina | 27103 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Vanderbilt Univeristy School of Medicine | Nashville | Tennessee | 37212-6303 | — |
| South Texas Accelerated Research Therapeutics (START) | San Antonio | Texas | 78229-3307 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
| Inova Health System IRB | Fairfax | Virginia | 22031 | — |
| USO-Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| University of Wisconsin-Madison Hospital and Health Clinic | Madison | Wisconsin | 53792-4108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04956640, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04956640 live on ClinicalTrials.gov.